Clinical Trials Logo

Clinical Trial Summary

The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg plus Abacavir/Lamivudine once daily versus Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (ATRIPLA® a trade mark of Bristol-Myers Squibb and Gilead Sciences LLC) over 48 weeks; non-inferiority will also be tested at Week 96. This study will be conducted in HIV-1 infected ART-naïve adult subjects. Long term antiviral activity, tolerability, safety, and development of viral resistance will be evaluated.


Clinical Trial Description

ING114467 is a Phase 3 randomized, double-blind, double dummy, active-controlled, multicenter, study conducted in approximately 788 HIV-1 infected ART-naïve subjects. Subjects will be randomized 1:1 one of the following treatment arms:

GSK1349572 50 mg plus abacavir/lamivudine fixed-dose combination once daily (approximately 394 subjects)

OR

Atripla once daily (approximately 394 subjects)

Analyses will be conducted at 48 weeks and 96 weeks. Subjects randomized to receive GSK1349572 and who successfully complete 96 weeks of treatment will continue to have access to GSK1349572 plus abacavir/lamivudine fixed-dose combination through the study until it is locally available-as long as they continue to derive clinical benefit, until they meet a protocol-defined reason for discontinuation, or until development of the compound is terminated.

ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01263015
Study type Interventional
Source ViiV Healthcare
Contact
Status Completed
Phase Phase 3
Start date February 1, 2011
Completion date December 3, 2015

See also
  Status Clinical Trial Phase
Completed NCT03327740 - PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)
Completed NCT00257621 - GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults Phase 2
Completed NCT01227824 - A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Phase 3
Completed NCT01597648 - A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivirâ„¢ Phase 1
Completed NCT01205243 - ZIAGEN® Post-marketing Surveillance
Withdrawn NCT01283100 - A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects. Phase 1
Completed NCT00450580 - HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults Phase 3
Completed NCT00440947 - Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection Phase 3
Completed NCT00549198 - KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects Phase 4
Completed NCT00481390 - Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients N/A
Completed NCT00242840 - Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir) Phase 3
Terminated NCT00197145 - Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects Phase 3
Completed NCT00089583 - 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection Phase 2
Completed NCT00044577 - New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects Phase 3
Terminated NCT00104429 - GW873140 In Combination With Combivir In HIV Infected Subjects Phase 2
Terminated NCT00102778 - GW873140 In Combination With Kaletra In HIV Infected Subjects Phase 2
Completed NCT00094523 - Fosamprenavir Versus Other Protease Inhibitors Phase 3
Completed NCT00046176 - A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients Phase 3
Terminated NCT00242879 - A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults Phase 2
Completed NCT00082394 - A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV Phase 4